CAMBRIDGE, Mass., Jan 28, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its fourth quarter and full year 2007 financial results on Monday, February 11, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EST.
CAMBRIDGE, Mass., Jan 31, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Tuesday, February 5, 2008 at 11:40 a.m.
CAMBRIDGE, Mass., Feb 08, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the BIO CEO & Investor Conference 2008 on Tuesday, February 12, 2008 at 10:15 a.m. EST.
CAMBRIDGE, Mass., Feb 11, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 6,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf
CAMBRIDGE, Mass., Feb 12, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 6,000,000 shares of its common stock in an underwritten offering at a price to the public of $17.14 per share.
Vertex Pharmaceuticals Announces Exercise of Over-Allotment Options by Underwriters of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes CAMBRIDGE, Mass., Feb 13, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
CAMBRIDGE, Mass., Feb 19, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of its public offerings of 6,900,000 shares of common stock, including 900,000 shares purchased by the underwriters pursuant to their over-allotment option, and $287.5
CAMBRIDGE, Mass., Feb 29, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that the Company will participate in an HCV panel, entitled: "HCV: Protease Inhibitors and Beyond" at Susquehanna Financial Group's Second Annual SIGnificant Investment Options in
- First hepatitis C protease inhibitor to begin Phase 3 clinical
development -
- Trial designed to confirm potential of telaprevir to increase
sustained viral response (SVR) rates with 24-week treatment duration -
CAMBRIDGE, Mass., Mar 14, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Cowen and Company 28th Annual Health Care Conference on Wednesday, March 19, 2008 at 8:00 a.m. EDT.
--Interim analysis of 14-day study of VX-770 shows a significant<br> improvement in lung function --<br><br> --Lung function data supported by corresponding improvements in<br> disease-related biomarkers--<br><br> --Results to be shared with health authorities in order to<br> identify the most rapid path forward --
CAMBRIDGE, Mass., Mar 31, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data related to its investigational hepatitis C protease inhibitor telaprevir will be featured in a late-breaker poster presentation during the 43rd Annual Meeting of the
CAMBRIDGE, Mass., Apr 07, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Canaccord|Adams Hepatitis C Conference on Wednesday, April 9, 2008 at 4:00 p.m. EDT.
CAMBRIDGE, Mass., Apr 07, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its first quarter 2008 financial results on Monday, April 21, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
--Telaprevir data in HCV patients who failed current therapies to<br> be presented at EASL--<br><br> --Pharmacokinetic analyses in HCV patients show potential for<br> twice-daily dosing of telaprevir--<br><br> --VX-770 for cystic fibrosis to advance based on positive results<br> reported in March 2008--
- High sustained virologic response (SVR) rates of 61% in PROVE 1<br> and 68% in PROVE 2 with 24-week telaprevir-based treatment regimen -<br><br> - Telaprevir first and only investigational HCV protease inhibitor<br> in Phase 3, ADVANCE trial underway -
-Interim results to be presented in late-breaker poster<br> presentation at EASL on April 24-<br><br> -Significant early on-treatment viral response from patients who<br> previously failed therapy-
CAMBRIDGE, Mass., Apr 28, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, April 30, 2008 at 4:20 p.m. EDT.
CAMBRIDGE, Mass., May 01, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Deutsche Bank 33rd Annual Health Care Conference on Monday, May 5, 2008 at 1:20 p.m. EDT.
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences CAMBRIDGE, Mass., May 06, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentations at the Bank of America 2008 Health Care
CAMBRIDGE, Mass., May 15, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2008 Annual Meeting of Stockholders. At the meeting, stockholders approved the amendment to Vertex's Articles of Organization increasing the number of
CAMBRIDGE, Mass., May 16, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 Citi Investment Research Global Healthcare Conference on Wednesday, May 21, 2008 at 1:00 p.m. EDT.
CAMBRIDGE, Mass., Jun 03, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has sold its rights to future royalties in Lexiva(R) and Agenerase(R) under its 1993 license agreement with GlaxoSmithKline plc (GSK) in the field of HIV protease inhibitors
CAMBRIDGE, Mass., Jun 06, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Goldman Sachs 29th Annual Global Healthcare Conference on Wednesday, June 11, 2008 at 4:00 p.m. PDT (7:00 p.m. EDT).
Vertex Establishes Early-Stage Huntington's Disease Research Collaboration with CHDI Foundation, Inc. -Vertex to receive up to $4 million in funding for Huntington's disease research- -Novel venture philanthropy model used in Vertex's Cystic Fibrosis R&D efforts to support new Huntington's disease
CAMBRIDGE, Mass., Jun 18, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Freda C. Lewis-Hall, M.D. as Executive Vice President, Medicines Development. Dr. Lewis-Hall joins Vertex from Bristol-Myers Squibb, Incorporated, and has
CAMBRIDGE, Mass., Jul 17, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2008 financial results on Thursday, July 31, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
-- Treatment-failure data and treatment-naive data strengthen<br> telaprevir's potential profile and highlight broad opportunity<br> in treatment of chronic hepatitis C virus (HCV) infection<br><br> -- VX-770, for cystic fibrosis (CF), completes enrollment for<br> 28-day Phase 2a study; 2009 targeted for initiation of<br> registration studies, pending 28-day study results
CAMBRIDGE, Mass., Aug 05, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 BMO Capital Markets Focus on Healthcare Conference on Wednesday, August 6, 2008 at 9:00 a.m. EDT.
CAMBRIDGE, Mass., Aug 08, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Canaccord Adams 28th Annual Global Growth Conference on Wednesday, August 13, 2008 at 8:30 a.m. EDT.
First HCV protease inhibitor in pivotal trial for this difficult<br> to treat patient population<br><br> Trial to enroll all major treatment-failure patient groups,<br> including null responders, partial responders and relapsers<br><br> Two telaprevir registration programs to address significant unmet<br> need in treatment-naive and treatment-failure patients
CAMBRIDGE, Mass., Aug 29, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Thomas Weisel Partners Healthcare Conference 2008 on Wednesday, September 3, 2008 at 8:00 a.m. EDT.
CAMBRIDGE, Mass., Sep 04, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 3rd Annual Citi Biotech Day on Monday, September 8, 2008 at 1:50 p.m. EDT and at the Morgan Stanley Global Healthcare Unplugged
CAMBRIDGE, Mass., Sep 17, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 7,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf
CAMBRIDGE, Mass., Sep 18, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 7,500,000 shares of its common stock in an underwritten offering at a price to the public of $25.50 per share, which would result in
CAMBRIDGE, Mass., Sep 19, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the UBS 2008 Global Life Sciences Conference on Wednesday, September 24, 2008 at 10:00 a.m. EDT.
CAMBRIDGE, Mass., Sep 22, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriter has exercised in full its option to purchase 1,125,000 shares of common stock at a public offering price of $25.50 per share.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX - News) today announced that key data on sustained viral response (SVR) rates in both treatment-naïve and treatment-failure genotype 1 hepatitis C (HCV) patients who received telaprevir-based treatment regimens
CAMBRIDGE, Mass., Sep 24, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today provided a correction to AASLD abstract 1854 published in the October 2008 supplement of the journal Hepatology. The title of the abstract is "Phase 2 Study of Telaprevir Administered q8h or
CAMBRIDGE, Mass., Oct 01, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the JMP Securities Healthcare Focus Conference on Monday, October 6, 2008 at 9:30 a.m. EDT.
CAMBRIDGE, Mass., Oct 16, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2008 financial results on Monday, October 27, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
<ul><li>VX-770 was well-tolerated when dosed as 150 mg and 250 mg twice daily for 28 days</li><li>VX-770 resulted in a significant increase in FEV1, and significant changes in sweat chloride and nasal potential difference, important markers of CFTR function</li>
<li>Researchers to present 28-day results at the North American Cystic Fibrosis Conference on October 23</li></ul>
<B><P>-- Phase 3 ADVANCE study of telaprevir in HCV completes enrollment --<br>
-- Registration program for VX-770 in cystic fibrosis being discussed with global authorities --<br>
-- As of September 30, 2008, Vertex had $920 million of cash, cash equivalents and marketable securities--</P></B>
New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection PROVE 3 data show 52% SVR12 in HCV treatment-failure patients with 24-week treatment duration PROVE 2 final results confirm 69% SVR in HCV treatment-naïve patients with 24-week
CAMBRIDGE, Mass., Nov 06, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at Deutsche Bank's 2008 Biotech Boston Confab on Tuesday, November 11, 2008 and at the Credit Suisse 2008 Healthcare Conference on Thursday,
CAMBRIDGE, Mass., Nov 14, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Lazard Capital Markets Healthcare Conference on Wednesday, November 19, 2008 at 2:30 p.m.
CAMBRIDGE, Mass., Nov 26, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Piper Jaffray 20 th Annual Health Care Conference on Tuesday, December 2, 2008 at 10:30 a.m.
CAMBRIDGE, Mass., Jan 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 27 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 1:30 p.m. PST (4:30 p.m. EST).